Vertical: CNMBase Year: 2025
Market Size (2025)
$43.79M
Projected (2032)
$59.04M
CAGR (2022–2032)
4.4%
Key Players
8+
Market Overview
The Global Medium-Chain Monoglycerides Feed Market was valued at USD 43.79 Million in 2025 and is projected to reach USD 59.04 Million by 2032, registering a CAGR of 4.36% over 2026–2032. Between 2025 and 2032 the market is expected to add USD 15.26 Million in absolute value. The market expanded from USD 38.51 Million in 2022 to USD 41.95 Million in 2024, reflecting steady adoption of medium-chain monoglycerides (MCMs) as functional feed additives in swine and poultry nutrition.
Medium-chain monoglycerides are glycerol esters of C6–C12 fatty acids, chiefly monolaurin (glycerol monolaurate), monocaprin and monocaprylin. They are used in compound feed, premixes and drinking water to support gut health, to control Gram-positive bacteria and enveloped viruses, and to reduce reliance on in-feed antibiotics. Demand is underpinned by antimicrobial-reduction policies in the European Union, the United States and China, by the continuing threat of African swine fever (ASF) and porcine epidemic diarrhoea virus (PEDV), and by the long-term expansion of poultry and pork production.
Key Findings
By Livestock: Swine is the largest segment, valued at USD 21.89 Million in 2025 (50.00% share). Others is the fastest-growing segment, with a CAGR of 5.27% over 2026–2032, followed by Poultry at 4.88%.
By Physical Form: Powder is the largest segment at USD 32.84 Million in 2025 (75.00% share). Liquid is the fastest-growing segment, with a CAGR of 5.55%.
By Region: Asia Pacific is the leading region, valued at USD 14.01 Million in 2025 (32.00% share). Middle East & Africa is the fastest-growing region, with a CAGR of 5.61%.
By Country: The U.S. is the leading country, valued at USD 7.13 Million in 2025. India is the fastest-growing country, with a CAGR of 7.63% over 2026–2032.
Segmentation Summary
By livestock, the market is divided into Swine, Poultry and Others. Swine accounted for USD 21.89 Million in 2025 and is expected to reach USD 28.30 Million by 2032. The segment benefits from the established use of monolaurin and MCM blends in piglet and sow diets and from feed-biosecurity programmes against ASF and PEDV. Poultry, valued at USD 17.52 Million in 2025, is projected to reach USD 24.46 Million by 2032 at a CAGR of 4.88%. Its growth reflects rising global broiler output and antibiotic-free production programmes. The Others segment, covering remaining livestock categories, is smaller at USD 4.38 Million in 2025 but grows fastest, at a CAGR of 5.27%.
By physical form, Powder products (MCMs on silica or other carriers, and spray-dried or granulated forms) held USD 32.84 Million in 2025 because they are compatible with premix and compound feed manufacturing. Liquid products, valued at USD 10.95 Million in 2025, are expected to grow at a CAGR of 5.55% to USD 15.99 Million by 2032. Growth is supported by drinking-water applications and liquid-application systems in feed mills.
Competitive Landscape Summary
The market is moderately consolidated at the top and fragmented in the tail. A small group of companies with confirmed MCM feed portfolios leads it. Adisseo (FRA® C12 range, from its acquisition of FRAmelco), BASF (BalanGut™ LS) and Eastman (Entero-Nova™) combine global distribution with in-house glyceride technology. Oleon (Avril Group), Proviron and Berg + Schmidt bring oleochemical integration or patented esterification know-how. Specialists such as Anitox, Natural Biologics and OlusPlus serve focused applications such as early-stage broiler nutrition and feed biosecurity. Competition centres on scientific substantiation, the alpha-monoglyceride content and purity of products, synergistic blends with short-chain glycerides, and technical service to integrators and premixers.
Challenges and Opportunities
The key challenges are price volatility in lauric oils (coconut and palm kernel oil), which supply the C8–C12 fatty acids used in MCM production, and competition from lower-cost organic acids, free medium-chain fatty acids, essential oils and probiotics. Efficacy also varies with product quality and inclusion strategy, and regulatory classifications and permissible claims differ between jurisdictions. Opportunities include drinking-water and liquid formats, rapid poultry expansion in India, Brazil, Saudi Arabia and South-East Asia, and combination products that pair MCMs with butyrate glycerides. Further opportunities lie in aquaculture and other species, and in post-zinc-oxide piglet nutrition in Europe.
Future Outlook
The market is expected to maintain steady growth through 2032, rising from USD 45.70 Million in 2026 to USD 59.04 Million in 2032. Asia Pacific will add the largest absolute value, USD 5.87 Million between 2025 and 2032, led by China and India. The Middle East & Africa and Latin America will outpace the global average, with CAGRs of 5.61% and 4.99% respectively. Liquid formats and poultry applications are set to gain share. Suppliers that pair robust efficacy data with consistent quality and regional technical support are best positioned to benefit.
The Medium-Chain Monoglycerides Feed Market market is projected to grow at a CAGR of 4.4% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Medium-chain monoglycerides (MCMs) are monoacylglycerols in which a single medium-chain fatty acid with six to twelve carbon atoms is esterified to the glycerol backbone. Feed-relevant MCMs include monocaproin (C6:0), monocaprylin (C8:0), monocaprin (C10:0) and monolaurin (C12:0, glycerol monolaurate or GML). Commercial products are produced by esterifying glycerol with medium-chain fatty acids derived mainly from coconut and palm kernel oil, or by glycerolysis. Distillation or purification is often used to raise the proportion of 1-monoglycerides (alpha-monoglycerides), which are regarded as the most biologically active form.
MCMs are amphiphilic molecules. They insert into and destabilise the lipid membranes of Gram-positive bacteria and the lipid envelopes of viruses. Compared with free medium-chain fatty acids, they are less dependent on low pH to remain active, less volatile and less odorous. In animal nutrition they are applied as gut-health and antimicrobial feed additives, as components of feed-biosecurity programmes, and as emulsifying and energy-supplying lipids.
Included in the scope: MCM-based feed additives in powder and liquid forms, both single-acid monoglycerides (such as monolaurin) and blends in which MCMs are a principal active component (such as combinations with short-chain glycerides or organic acids). These products are supplied to feed mills, premixers, integrators and farms for swine, poultry and other livestock.
Excluded from the scope: free medium-chain fatty acids sold without glyceride esterification; medium-chain triglycerides used purely as energy sources; short-chain glycerides (such as monobutyrin and tributyrin) sold as standalone products; MCMs for human food, pharmaceutical, cosmetic and personal-care applications; and mono- and diglycerides used only as technological emulsifiers in food processing.
Scope of the Study
The study covers the global market for medium-chain monoglycerides used in animal feed. It is segmented by livestock and by physical form, with regional and country-level analysis, exactly as set out in the market data.
Research Objectives
To define medium-chain monoglycerides for animal feed and to delineate the product scope relative to free fatty acids, triglycerides and short-chain glycerides.
To estimate the market size for 2022–2025 and to forecast it for 2026–2032 in USD Million, at global, regional and country levels.
To analyse the market by livestock (Swine, Poultry, Others) and by physical form (Powder, Liquid), and to identify the largest and fastest-growing segments.
To assess how antibiotic growth-promoter bans, antimicrobial-stewardship regulations and zinc oxide restrictions affect MCM demand.
To evaluate the role of MCMs in feed-biosecurity programmes against ASF, PEDV and other enveloped viruses.
To examine the value chain from lauric-oil feedstocks to end users, including the influence of raw material price volatility.
To profile leading suppliers of MCM feed additives and to track product launches, acquisitions, partnerships and expansions from 2022 onward.
To identify growth opportunities in emerging livestock markets and in liquid and drinking-water formats.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured, multi-stage research process. It began with a definition of the market and its scope, then moved through extensive secondary research and primary research with participants across the value chain. Market size was estimated with both top-down and bottom-up approaches, and the results were triangulated before the forecast was built. Each stage was reviewed for internal consistency so that segment, regional and country values reconcile with the overall market total.
Stage 1 – Scoping: definition of MCMs for feed, inclusion and exclusion criteria, and the segmentation framework.
Stage 2 – Secondary research: collection of data on livestock populations, feed production, additive regulations, company activity and trade.
Stage 3 – Primary research: validation of assumptions, pricing, adoption rates and growth expectations with industry participants.
Stage 4 – Market estimation: top-down and bottom-up sizing, followed by data triangulation.
Stage 5 – Forecasting and validation: projection to 2032 and a consistency review of the final dataset.
Secondary Research
Secondary research drew on sources relevant to the livestock feed and feed additive industry:
Industry associations: national and international feed manufacturer and feed additive associations, poultry and pork producer organisations, and oleochemical industry bodies.
Government and regulatory bodies: agricultural ministries, food safety authorities and veterinary agencies. These supply statistics on livestock populations, meat production, feed output, feed additive authorisations and antimicrobial-use restrictions.
Intergovernmental organisations: statistical databases and agricultural outlooks covering livestock and meat production, and animal-health situation reports on transboundary diseases.
Company sources: annual reports, investor presentations, product literature, technical bulletins and press releases from feed additive manufacturers, oleochemical producers and premixers.
Trade and scientific journals: feed industry trade publications and peer-reviewed animal science, veterinary and microbiology journals reporting on the efficacy of MCMs.
Paid databases: trade and customs databases, company financial databases and patent databases, used to track trade in glycerides and fatty-acid esters and innovation activity.
Primary Research
Primary research consisted of in-depth interviews with participants on both the supply side and the demand side. It was used to validate secondary findings, fill information gaps and gather qualitative insight into market dynamics.
Supply side: executives, product managers and technical sales managers of MCM and feed additive manufacturers; oleochemical producers supplying medium-chain fatty acids and glycerol; and distributors and premix companies.
Demand side: nutritionists and procurement managers at compound feed mills and integrated swine and poultry producers; farm veterinarians; and animal nutrition consultants.
Objectives: to validate market size and segment splits, understand pricing and inclusion practices, assess adoption by species and form, identify regional regulatory influences, and gauge expectations for growth and competition.
Market Size Estimation
Top-down approach: the global feed additive market was used as the starting point. The share attributable to gut-health and antimicrobial-alternative additives was estimated, and then the share of MCM-based products within it. This was applied by region and species using livestock population and feed production statistics.
Bottom-up approach: compound feed production by species and country was combined with estimated MCM penetration rates, typical inclusion levels and average selling prices to derive country-level demand. This was then aggregated to regional and global totals. Supplier-level revenue estimates for MCM portfolios were used as a cross-check.
Data triangulation: results from the two approaches were compared and reconciled with insights from primary interviews. Where estimates diverged, assumptions on penetration, pricing and product mix were revisited until a consistent dataset was reached.
Forecasting Methodology
The forecast for 2026–2032 was developed by projecting the base-year (2025) market by segment and country. The projection combines quantitative drivers with qualitative adjustments from primary research. Factors considered include: projected growth in swine, poultry and other livestock production and in compound feed output; regulatory trajectories on antibiotic use, medicated zinc oxide and feed additive authorisation; the incidence and geographic spread of ASF, PEDV, avian influenza and other diseases that influence feed-biosecurity spending; adoption trends for liquid and drinking-water applications; price trends for lauric oils and glycerol, and their pass-through to MCM prices; competitive intensity from alternative additives and the pace of new product introductions.
Assumptions and Limitations
Market values are expressed in nominal USD Million. Constant exchange rates are assumed over the forecast period.
No major new restriction on the use of MCMs in feed is assumed in any covered jurisdiction during the forecast period.
Disease outbreaks such as ASF and avian influenza are assumed to follow historical patterns. A severe new pandemic-scale outbreak could change demand materially.
Lauric oil supply is assumed to remain adequate, although price volatility is factored into the analysis.
Where companies do not disclose MCM-specific revenue, supplier-level estimates rely on triangulation and primary research.
Values for "Rest of" country groupings are aggregated and do not represent individual countries.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The medium-chain monoglycerides feed market is moderately consolidated among a small group of companies with confirmed MCM portfolios and fragmented in its long tail. The leading group includes diversified animal nutrition and chemical companies, namely Adisseo, BASF and Eastman. Each combines proprietary glyceride technology with global sales and technical service networks. A second group comprises oleochemical and specialty chemical companies, such as Oleon, Proviron and Berg + Schmidt, that use integration into fatty-acid chemistry or patented esterification processes. Specialists such as Anitox, Natural Biologics and OlusPlus focus on particular applications or channels. Regional producers, particularly in China, supply lower-cost monolaurin products to compound feed manufacturers.
Competition is based mainly on technical differentiation rather than price. The key factors are the alpha-monoglyceride content and purity of products, the breadth of the fatty-acid profile, synergistic combinations with short-chain glycerides and organic acids, the depth of efficacy data from trials, and the quality of on-farm and feed-mill technical support. Since 2022, strategic activity has centred on product launches in new formats (liquid and drinking-water products), extension into early-life broiler and piglet nutrition, research supporting immunity and antiviral positioning, and portfolio reshaping through acquisitions and divestments in the wider animal nutrition business.
Key Player Positioning
Based on product portfolio breadth, geographic reach, technological capability and strategic activity, the profiled companies are positioned as follows:
Leaders: Adisseo, BASF and Eastman. They have broad MCM and glyceride portfolios in both powder and liquid forms, global distribution, and strong R&D and technical service capabilities.
Challengers: Oleon (Avril Group), Proviron and Berg + Schmidt. They have strong oleochemical or esterification expertise, dedicated MCM product lines and a growing international presence, with portfolios focused on lipid-based solutions.
Niche players: Anitox, Natural Biologics and OlusPlus. They have focused portfolios targeting specific applications such as early-stage broiler nutrition, feed biosecurity or monolaurin supply, and they compete on specialisation and technical expertise.
Adisseo
Overview: Headquartered in Antony, France, and founded in 1939, Adisseo is one of the world's leading animal nutrition companies, with Methionine, Vitamins and Specialties business units. It is listed in Shanghai as Bluestar Adisseo Co. and is part of China National Bluestar. Its MCM capability comes from the acquisition of FRAmelco (Raamsdonksveer, the Netherlands), a specialist in glycerides of short- and medium-chain fatty acids, announced in September 2020.
Revenue: CNY 17.23 billion (FY2025), including Specialties revenue of CNY 4.32 billion.
Relevant products: FRA® C12 Dry and FRA® C12 Liquid (alpha-monoglycerides of lauric acid); FRA® Gut Protect (short- and medium-chain fatty acids with C12 glycerides and tributyrin); FRA® Butyrin Hybrid (butyric glycerides with alpha-monoglycerides).
Key developments: January 2023: acquired Nor-Feed, a plant-extract specialist, to expand its Specialties portfolio. 2024: presented in vitro data on the activity of lauric glycerides against PRRSV, and positioned FRA® C12 for swine immunity. October 2025: promoted FRA® C12 Liquid for drinking-water use and FRA® Gut Protect for poultry. FY2025: a specialties blending facility in Nanjing supported 23 locally made products in China.
Strategy: Adisseo is growing its Specialties business through acquisitions and local production in China, and positions its FRA® glyceride range as an antibiotic-reduction, immunity and antiviral tool.
BASF SE
Overview: Headquartered in Ludwigshafen, Germany, and founded in 1865, BASF is the world's largest chemical company. Animal nutrition is part of its Nutrition & Care segment, which supplies vitamins, enzymes and feed ingredients.
Revenue: EUR 59,657 million (FY2025).
Relevant products: BalanGut™ LS P (powder) and BalanGut™ LS L (liquid), based on monoglycerides of butyric, caprylic and capric acids, for pigs, chickens and turkeys; BalanGut™ AQ, based on monoglycerides of butyric, propionic and caproic acids, for aquaculture.
Key developments: 2024–2025: supported peer-reviewed studies on BalanGut™ LS in E. coli-challenged weaned pigs and in Brazil. October 2025: began a strategic review of its feed enzymes business. November 2025: signed a binding agreement to sell its global glycinate business to Biochem.
Strategy: BASF is focusing its animal nutrition portfolio on core ingredients and positions BalanGut™ as a gut-health solution for antibiotic-reduction programmes, available in both powder and liquid forms.
Eastman Chemical Company
Overview: Headquartered in Kingsport, Tennessee, U.S., and founded in 1920, Eastman is a global specialty materials company. Its animal nutrition business supplies organic acids and their derivatives. It strengthened its organic acid derivatives capability through the acquisition of 3F Feed & Food (Spain) in 2021.
Revenue: USD 8,752 million (FY2025).
Relevant products: Eastman Entero-Nova™ line: Entero-Nova™ 400 (short- and medium-chain monoglyceride blends), Entero-Nova™ 500 (organic acids with short- and medium-chain monoglycerides) and Entero-Nova™ 800 (glycerides of short- and medium-chain fatty acids).
Key developments: 2023: expanded technical communication on combining monoglycerides and organic acids in gut-health strategies. 2024: the Entero-Nova™ range was evaluated in university swine research.
Strategy: Eastman combines organic acids and monoglycerides in solutions tailored to each customer for swine, poultry and aquaculture, drawing on its global specialty chemicals platform.
Oleon NV (Avril Group)
Overview: Oleon is a Belgian oleochemical producer with its main site in Ertvelde. It employs about 1,000 people and has production sites in Belgium, Germany, France, the U.S. and Malaysia. Avril Group acquired the company in 2008. Through its feed business it supplies glycerides, emulsifiers and medium-chain triglycerides to the animal nutrition industry.
Revenue: Oleon does not publish standalone revenue. Its parent, Avril Group, reported revenue of EUR 6.854 billion for FY2021.
Relevant products: RADIAMULS MG 2549V (at least 90% glycerol monolaurate, high alpha-monoglyceride content, carrier-free); RADIAMULS MG 2440V (glycerol monolaurate on vegetable fat); RADIAMULS MCT range (C8/C10).
Key developments: December 2023: presented its glycerol monolaurate portfolio for broilers and swine. November 2024: showcased its animal feed and glycerol monolaurate portfolio at EuroTier 2024.
Strategy: Oleon uses its integration in lauric oleochemistry and esterification to grow its animal nutrition business with emulsifiers, MCT energy sources and antimicrobial monoglycerides.
Proviron
Overview: Founded in 1977 and headquartered in Hemiksem, Belgium, Proviron is a privately held chemical company. Its business units include fine chemicals, plasticisers and an animal health division that supplies feed additives based on proprietary monoglyceride technology.
Revenue: Privately held; revenue not publicly disclosed.
Relevant products: Optigut (glycerides of short- and medium-chain fatty acids, including monolaurin and butyrin) for poultry; Porcestin (mono- and triglycerides of butyric and lauric acid) for weaned piglets; Optigut Aqua for shrimp.
Key developments: January 2025: was granted European patent EP3840587B1 covering the use of monolaurin and glycerol tributyrate combinations in suckling-pig feed.
Strategy: Proviron applies patent-protected esterification know-how to monolaurin and butyrin combinations, which it positions as antibiotic alternatives for swine, poultry and aquaculture.
Berg + Schmidt
Overview: Berg + Schmidt, headquartered in Hamburg, Germany, is a functional-lipids specialist and part of the family-owned Stern-Wywiol Gruppe. It develops lipid-based solutions for animal nutrition, including monoglycerides, medium-chain fatty acids and medium-chain triglycerides.
Revenue: Not publicly disclosed at company level. Its parent, Stern-Wywiol Gruppe, reported sales of EUR 520 million for FY2017.
Relevant products: LipoVital range (monoglycerides, MCFA and MCT, in liquid and powder forms); LipoVital WS (water-soluble monoglycerides of short- and medium-chain fatty acids for drinking water); LipoVital Protect Aqua.
Key developments: November 2024: launched LipoVital WS for drinking-water application at EuroTier 2024.
Strategy: Berg + Schmidt is building a lipid-based gut-health and biosecurity toolbox and extending it into drinking-water formats.
Anitox (Iluma Alliance)
Overview: Founded in 1977 and headquartered in Lawrenceville, Georgia, U.S., Anitox is a feed safety and pathogen-control specialist operating in 68 countries. Its brands include Termin-8 and Finio. It became part of Iluma Alliance in 2024.
Revenue: Privately held; revenue not publicly disclosed.
Relevant products: AvrX™ Prime, a proprietary blend of short- and medium-chain monoglycerides for early-stage broiler nutrition.
Key developments: July 2024: acquired by Iluma Alliance. July 2026: launched AvrX™ Prime at the World's Poultry Congress in Toronto.
Strategy: Anitox is expanding from feed hygiene and pathogen control into gut health with monoglyceride technology, using its established international distribution.
Natural Biologics Inc.
Overview: Founded in 2015 and based in Newfield, New York, U.S., Natural Biologics is an animal health company focused on natural antimicrobial and antiviral solutions. It has played a prominent role in scientific work on medium-chain monoglycerides, including research on glycerol monolaurate and ASF virus. It is the U.S. logistics partner for Nor-Feed products.
Revenue: Privately held; revenue not publicly disclosed.
Relevant products: Optishield, a formulation of monoglycerides with surfactants and oligosaccharides for swine feed biosecurity.
Key developments: October 2022: its scientists published a review of antimicrobial monoglycerides for swine and poultry applications.
Strategy: Natural Biologics positions MCMs as science-based tools for feed biosecurity and antiviral protection, working with research institutions and distribution partners.
OlusPlus B.V.
Overview: OlusPlus is a Dutch family-owned company based in Hasselt, the Netherlands. It supplies monoglyceride-based feed additives together with rumen bypass fats.
Revenue: Privately held; revenue not publicly disclosed.
Relevant products: Olus® C12 (monolaurin); Olus® AC34 (monoglyceride-based blend); Olus® Plus C4 (monobutyrin).
Key developments: August 2026: published in vitro test results for Olus® AC34 against Salmonella and E. coli.
Strategy: OlusPlus focuses on a niche portfolio of monoglycerides alongside fat products for ruminants and serves feed manufacturers through technical support.
Threat of New Entrants – Medium
Esterification technology is well understood and oleochemical producers can enter with limited capital investment.
However, credible efficacy data, regulatory registrations and technical service networks take years to build.
Established relationships with integrators and premixers favour incumbents.
Bargaining Power of Suppliers – Medium
Medium-chain fatty acid supply depends on a limited number of lauric-oil-producing countries and large oleochemical companies.
Vertically integrated producers such as oleochemical groups face lower supplier risk.
Glycerol is widely available, which reduces the leverage of glycerol suppliers.
Bargaining Power of Buyers – High
Large integrators and feed mill groups purchase in volume and run comparative trials across additive suppliers.
Many substitute gut-health additives are available, strengthening buyers' negotiating position.
Cost per tonne of feed is closely scrutinised, especially in periods of low livestock margins.
Threat of Substitutes – High
Organic acids, free MCFAs, essential oils, probiotics, prebiotics and enzymes compete for the same application.
Substitutes are often cheaper and already included in standard premix formulations.
However, the specific activity of MCMs against enveloped viruses and Gram-positive bacteria gives them a differentiated role.
Competitive Rivalry – Medium
A limited number of global suppliers hold confirmed MCM portfolios, and they compete through technical differentiation rather than price alone.
Regional specialists and low-cost producers intensify competition in price-sensitive markets.
Patents on specific blends and applications support differentiation.
Threat of new entrants: Medium; Accessible technology, but high barriers in efficacy data and customer relationships.
Bargaining power of suppliers: Medium; Concentrated lauric-oil supply; integration reduces risk.
Bargaining power of buyers: High; Large integrators, trial-based procurement, many alternatives.
Threat of substitutes: High; Wide range of alternative gut-health additives.
Competitive rivalry: Medium; Few global specialists; competition based on technical differentiation.
Market estimates by geography (2032)
InsightAsia Pacific leads with $19.88M by 2032, while Middle East & Africa is projected to grow fastest at a 5.5% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $8.58M | $10.39M | $12.54M | 3.9% | 21% |
| Europe | $10.98M | $13.09M | $15.41M | 3.4% | 26% |
| Asia Pacific | $12.13M | $15.50M | $19.88M | 5.1% | 34% |
| Latin America | $4.95M | $6.28M | $8.00M | 4.9% | 14% |
| Middle East & Africa | $1.88M | $2.44M | $3.21M | 5.5% | 5% |
| Total | $38.51M | $47.70M | $59.04M | 4.4% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$59.04M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Swine | $28.30M | 3.8% | 48% |
| Poultry | $24.46M | 4.8% | 41% |
| Others | $6.28M | 5.3% | 11% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Medium-Chain Monoglycerides Feed Market covering market dynamics, competitive landscape, and strategic outlook.
The Medium-Chain Monoglycerides Feed Market market is projected to reach $59.04M by 2032, growing at 4.4% CAGR. The Swine segment holds the largest share.
The market is shaped by regulatory pressure to reduce antimicrobial use in livestock, by the need to protect herds and flocks from feed-borne and enveloped viral pathogens, and by the long-term growth of global meat and feed production. Raw material price volatility, competition from alternative additives and uneven regulatory treatment of efficacy claims act as restraints. The growth factor analysis below rates the relative impact of five macro and five micro factors over three forecast windows. The impact scores (out of 10) are analyst assessments based on secondary research and primary interviews.
Restrictions on Antibiotic Growth Promoters and Antimicrobial Stewardship
Regulatory action against routine antibiotic use in livestock is the most important structural driver of the MCM feed market. The European Union banned antibiotics as growth promoters in animal feed from 1 January 2006 under Regulation (EC) No 1831/2003. Regulation (EU) 2019/6 on veterinary medicinal products, applicable since January 2022, further restricts prophylactic and metaphylactic antimicrobial use. In the United States, Guidance for Industry #213 ended growth-promotion uses of medically important antimicrobials from 1 January 2017, and the Veterinary Feed Directive brought remaining in-feed uses under veterinary oversight. China's Ministry of Agriculture and Rural Affairs Announcement No. 194 withdrew growth-promoting drug feed additives from 1 January 2020, with feed mills required to stop producing feeds containing them from 1 July 2020. India prohibited colistin for food-producing animals and in feed supplements in 2019. These measures have pushed nutritionists towards non-antibiotic tools that control Gram-positive pathogens such as Clostridium perfringens and Streptococcus suis. MCMs, and monolaurin in particular, are well suited to this role, which supports sustained demand across all regions.
Feed Biosecurity against African Swine Fever and PEDV
Feed and feed ingredients have been identified as potential vehicles for transmitting viral pathogens. This has made in-feed mitigants part of biosecurity programmes, particularly in swine. According to the World Organisation for Animal Health (WOAH), 83 countries have reported ASF since 2005, and twelve reported a first occurrence between January 2022 and January 2025. In a peer-reviewed laboratory study, Jackman et al. (2020) reported that glycerol monolaurate included at 2% in feed reduced ASF virus infectivity by more than 88% at 30 minutes. Research at Kansas State University has shown dose-dependent reductions in ASF virus infectivity with medium-chain fatty acid-based additives. Earlier studies showed that medium-chain fatty acid blends can prevent PEDV infection through contaminated feed. MCMs act on the lipid envelope that ASF virus, PEDV and porcine reproductive and respiratory syndrome virus all share. Many suppliers therefore position them as part of a layered biosecurity strategy, which supports demand from integrators and feed mills in regions exposed to ASF.
Expansion of Global Feed and Meat Production
MCM demand is closely linked to compound feed output for swine and poultry. The 2026 Alltech Agri-Food Outlook estimated global feed production at 1.44 billion tonnes in 2025, up 2.9% year on year. Broiler feed rose 3.7% to 400.4 million tonnes and pig feed rose 3.0% to 380.9 million tonnes. China, the United States, Brazil and India were the largest feed-producing countries. The OECD-FAO Agricultural Outlook 2026–2035 projects that global meat consumption will increase by about 12% by 2035, with poultry accounting for the largest increase. This growth will be concentrated in Asia, Latin America and Africa, where integrators are scaling up production and adopting more sophisticated nutrition programmes. As production intensifies, stocking densities rise and the economic cost of enteric disease grows. This increases the value of additives that support gut integrity and feed efficiency, and so widens the base of feed tonnage to which MCMs can be applied.
Gut Health Management in Young Animals and the Phase-Out of Medicinal Zinc Oxide
The weaning transition in piglets and the first weeks of life in broilers are the periods of greatest enteric vulnerability, and they account for a large share of MCM use. In the European Union, veterinary medicinal products containing zinc oxide for oral use in food-producing animals were withdrawn from June 2022. This removed a widely used tool for controlling post-weaning diarrhoea, and producers have since adopted multi-component nutritional strategies that combine MCMs, butyrate glycerides, organic acids and fibre sources. Suppliers have responded with targeted products, including monolaurin and tributyrin combinations for suckling and weaned pigs and short- and medium-chain monoglyceride blends for early-stage broilers. Research on immune modulation, including in vitro work on lauric glycerides and porcine viruses, is broadening the value proposition beyond antibacterial action.
Liquid and Drinking-Water Applications
Liquid MCM formulations that can be dosed through drinking water or applied after pelleting allow fast, targeted intervention during disease challenges and avoid heat damage during feed processing. Recent introductions of water-soluble monoglyceride products and drinking-water protocols for poultry show supplier interest in this channel. The Liquid segment is the fastest-growing physical form, with a CAGR of 5.55% over 2026–2032.
Emerging Livestock Markets
Rapid expansion of integrated poultry and swine production in India, Brazil, South-East Asia, Saudi Arabia and Africa offers significant headroom. Antibiotic-reduction policies are tightening in these markets and MCM penetration remains low. India is the fastest-growing country market, with a CAGR of 7.63%. The Middle East & Africa is the fastest-growing region, at 5.61%.
Combination Products and New Species
Pairing MCMs with short-chain glycerides (monobutyrin and tributyrin), organic acids or plant extracts produces differentiated, patent-protected products with broader activity. Aquaculture (shrimp and fish), ruminant calves and companion animals are emerging application areas that can extend MCM use beyond swine and poultry.
Raw Material Price Volatility
Caprylic, capric and lauric acids are derived mainly from coconut and palm kernel oil. Prices of these lauric oils are affected by weather events, replanting cycles, export policies in producing countries and competing demand from the oleochemical, food and personal-care industries. Glycerol prices are linked to biodiesel production. Because MCMs carry a price premium over many alternative additives, raw material spikes reduce the cost advantage at farm level and can lead price-sensitive feed mills to cut inclusion rates or switch to cheaper products.
Variable Efficacy and Regulatory Classification
Field results with MCMs depend on product composition, the proportion of alpha-monoglycerides, inclusion levels, diet composition and disease pressure. This creates variability that can undermine adoption among sceptical nutritionists. In addition, MCM products may be marketed as feed materials, technological additives or zootechnical additives depending on the jurisdiction. This limits the health and performance claims suppliers can make and raises the cost and time needed to register products in new markets.
Competition from Alternative Additives
MCMs compete for the same gut-health budget as organic acids, free medium-chain fatty acids, essential oils and other phytogenics, probiotics, prebiotics and enzymes. Many of these alternatives are cheaper per tonne of feed or already embedded in premix formulations. As a result, MCMs must demonstrate a clear return on investment to secure inclusion.
Shift towards Synergistic Glyceride Blends
Leading suppliers increasingly offer blends of short- and medium-chain monoglycerides, sometimes combined with organic acids, rather than single-acid products. Examples include BASF's BalanGut™ LS, Eastman's Entero-Nova™ line and Adisseo's FRA® Gut Protect. The aim is to cover a broader antimicrobial spectrum and to support gut tissue development at the same time.
Immunity and Antiviral Positioning
Product positioning is moving from pure antibacterial action towards immunity support and antiviral activity against enveloped viruses. Research on PRRSV, ASF virus and PEDV underpins this shift, and suppliers are investing in in vitro, challenge and field trials to support it.
Sustainable and Traceable Feedstocks
Feed customers and downstream food retailers are paying more attention to the sustainability of palm-derived inputs. This is encouraging the use of certified palm kernel and coconut-derived fatty acids and greater supply-chain traceability.
Claims Substantiation and Regulatory Approval
Regulators in the EU, the US and other markets allow health and antiviral claims for feed products only after robust evaluation. Building dossiers that satisfy these requirements remains a significant challenge, especially for smaller suppliers.
The MCM feed value chain runs from lauric-oil feedstocks through oleochemical processing and glyceride synthesis to formulation, distribution and on-farm use.
Jan 2023: Adisseo; Acquisition; Acquired Nor-Feed, a plant-extract specialist, to expand its Specialties portfolio.
Dec 2023: Oleon (Avril Group); Product launch; Introduced RADIAMULS MG 2549V (at least 90% glycerol monolaurate) and MG 2440V for poultry and swine premixes.
May 2024: Adisseo; Product development; Presented in vitro data showing that lauric glycerides reduce PRRSV titres in porcine macrophages.
Jul 2024: Anitox / Iluma Alliance; Acquisition; Iluma Alliance acquired Anitox.
Sep 2024: Adisseo; Product launch; Positioned FRA® C12 and FRA® Butyrin Hybrid for swine immunity support.
Nov 2024: Oleon (Avril Group); Expansion; Showcased its glycerol monolaurate feed portfolio at EuroTier 2024.
Nov 2024: Berg + Schmidt; Product launch; Launched LipoVital WS, water-soluble short- and medium-chain monoglycerides for drinking water.
Jan 2025: Proviron; Product development; Granted European patent EP3840587B1 for monolaurin and tributyrin in suckling-pig feed.
Oct 2025: Adisseo; Product launch; Introduced FRA® C12 Liquid drinking-water application and FRA® Gut Protect for poultry.
Nov 2025: BASF SE / Biochem; Acquisition (divestment); Signed a binding agreement to sell its global glycinate business to Biochem.
Mar 2026: Adisseo; Expansion; Reported that its Nanjing specialties blending facility supported 23 locally made products in China in 2025.
Jul 2026: Anitox; Product launch; Launched AvrX™ Prime, a short- and medium-chain monoglyceride blend for early-stage broilers.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 32 companies operating in the Medium-Chain Monoglycerides Feed Market market, including revenue, employee count, and market positioning where available.
Showing 32 of 32 companies
### Identity and listing | Field | Detail | |---|---| | Entity profiled | Eastman Chemical Company (exact legal-name match; active; publicly listed) | | Listing status vs. input list | Confirmed public company — matches the type supplied | | Former names / predecessors | Tennessee Eastman Company / Corporation (Kodak's chemical subsidiary, founded 1920); Eastman Chemical Products (marketing arm); operated as Eastman Kodak's chemicals division until spin-off | | Founding year | 1920 (Kingsport, Tennessee, by George Eastman) | | Incorporation | Delaware, 1993 (2026 Proxy, "Eastman at a Glance") | | Spin-off from Eastman Kodak | Effective 31 Dec 1993; NYSE trading from early January 1994 | | Headquarters | 200 South Wilcox Drive, Kingsport, Tennessee 37660, USA | | Exchange / ticker | New York Stock Exchange: EMN | | ISIN / CUSIP | US2774321002 / 277432100 (standard identifiers; not re-checked against filing cover page) | | Fiscal year end | 31 December | | Auditor | PricewaterhouseCoopers LLP (ratified for FY2026 at 7 May 2026 AGM; lead partner rotated in 2026) | | Website | www.eastman.com | | Market capitalization | USD 7.39 billion (5 Oct 2026, share price USD 64.62; 114.33 million shares) | | Enterprise value | USD 12.16 billion (S&P Global via StockAnalysis, 5 Oct 2026) | | Credit ratings | Moody's Baa2 (outlook negative, changed ~Aug 2026); S&P BBB (outlook negative since Aug 2025, affirmed Nov 2025); Fitch: BBB historically (current outlook n/v) | | CEO & Board Chair | Mark J. Costa (CEO since January 2014) | | Customers served | More than 100 countries | | Metric | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Employees (approx., headcount) | 14000 | 14000 | 13000 | Sources: FY2024 headcount from company boilerplate in August 2025 releases ("approximately 14,000"); FY2025/2026 from FY2025 results release and 2026 Proxy ("approximately 13,000"). The roughly 7% reduction between 2024 and 2025 aligns with corporate severance charges of USD 34 million booked in FY2025 (FY2025 financial tables, Table 3A note 7). Eastman is a ~USD 8.8 billion, Kingsport-headquartered specialty materials producer whose competitive identity rests on deeply integrated, largely U.S.-based asset complexes in Tennessee and Texas that convert coal-derived syngas, cellulose, propane and—increasingly—waste plastic into higher-value polymers, films, additives and fibers. Roughly two-thirds of revenue comes from two specialty segments (Advanced Materials and Additives & Functional Products) anchored by franchise brands such as Saflex interlayers, LLumar window films, Tritan copolyester, Therminol heat-transfer fluids and Naia textiles. The remaining third—Chemical Intermediates and Fibers—supplies scale, integration economics and cash but carries commodity cyclicality and structural decline risk (acetate tow). Management's differentiator is an "innovation-driven growth model" layered with a circular-economy platform (Kingsport methanolysis molecular recycling). The investment debate centres on whether innovation and circularity can outrun cyclical demand, an elevated 3x+ leverage profile, and a decade of flat-to-declining revenue. --- ### Company's own description (paraphrased from FY2025 releases and 2026 Proxy) Eastman describes itself as a global specialty materials company that produces a broad range of products found in everyday items, with a stated purpose of enhancing the quality of life in a material way. It attributes its growth to an innovation-driven model built on world-class technology platforms, deep customer engagement and differentiated application development, which it uses to grow leading positions in attractive end markets—explicitly naming transportation, building and construction, and consumables. The 2026 Proxy adds that its strategy is founded on innovating sustainable solutions and maintaining its social license to operate, framed around a "triple challenge" of carbon neutrality, circularity and caring for society. ### Independent characterization Eastman is best understood as a hybrid specialty/intermediates producer whose specialty franchises sit on top of integrated commodity-like streams. Four integrated technology streams underpin the portfolio: 1. **Acetyl/cellulosics stream (Kingsport):** coal gasification produces syngas → methanol → acetic acid/acetic anhydride; combined with wood pulp to make cellulose esters (cellulose acetate flake, CAB, CAP). Outputs feed acetate tow and textile yarn (Fibers), cellulose-ester coatings additives (AFP), and cellulose-based plastics (AM). 2. **Polyester/copolyester stream (Kingsport):** proprietary monomers (e.g., CHDM, TMCD) enable Tritan and Eastar copolyesters; the methanolysis molecular-recycling unit depolymerizes polyester waste back into monomers that substitute for virgin feedstock. 3. **Olefins/oxo stream (Longview, Texas — second-largest site):** propane/ethane cracking → propylene/ethylene → oxo alcohols, plasticizers, glycol ethers and solvents (Chemical Intermediates), plus feedstock for specialty additives. 4. **Alkylamines and specialty fluids (Taminco/Solutia heritage):** methylamines, ethylamines and higher amines for agriculture, water treatment, personal care and pharma; Therminol heat-transfer fluids and Skydrol aviation hydraulic fluids. ### Revenue model | Revenue type | Share of revenue | Comment | |---|---|---| | Product sales (B2B) | ~99%+ | Essentially all revenue is from manufactured-product sales under spot, contract and cost-pass-through arrangements | | Technology licensing | Not separately disclosed (immaterial) | Oxo process technology licensing; APAC licensing programs were discontinued in 4Q2025 (USD 13 million adjustment in CI segment) | | Services / subscription | None material | Technical service is bundled with product sales | Pricing mechanisms (FY2025 releases): AFP uses cost-pass-through contracts for a meaningful share of volume (price +3% in FY2025 explicitly attributed to them); Fibers acetate tow is sold under annual contracts with minimum commitments (2Q2026 call: tow volumes rise in 2H as customers meet annual minimums); CI is spread-driven against propane/ethylene and Asian competition; AM is value-priced (management "defended price" in 4Q2025 despite volume declines). ### Value-chain position Eastman sits in the mid-stream to downstream of the chemical value chain: it is backward-integrated into basic feedstocks (syngas, olefins) but sells primarily to converters and OEM tier suppliers—windshield laminators, film converters/installers, plastic molders, coatings formulators, agrochemical formulators, cigarette-filter makers and textile mills—rather than to consumers. Brand recognition at consumer level exists for a few franchises (LLumar films, Tritan in drinkware, Naia in apparel), which supports co-branding and pricing. ### Customer types and end markets The 2026 Proxy lists FY2025 revenue by end-use market across: Transportation; Building and Construction; Consumables; Durables and Electronics; Personal Care and Wellness; Filter Media; Medical and Pharma; Industrial Chemicals; Food, Feed and Agriculture; Water Treatment and Energy; and Other Markets. The proxy states 56% of revenue arises outside North America (FY2025). Customer concentration: no single customer is disclosed as ≥10% of sales in sources reviewed (n/v).
BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital. --- **The company's own description.** BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions. **Independent characterization.** BASF is best understood as three businesses under one roof: 1. **An integrated commodity and intermediates engine** (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025). 2. **Formulated and performance products** (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary). 3. **Standalone franchises** with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million. **Revenue model.** Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported). **Value chain position.** Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024. **Customers and end-markets.** BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.
3 interactive charts drawn from the Medium-Chain Monoglycerides Feed Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Medium-Chain Monoglycerides Feed Market By Physical Form
Global Medium-Chain Monoglycerides Feed Market By Livestock
Global Medium-Chain Monoglycerides Feed Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
